blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1390075

EP1390075 - CHEMOTHERAPEUTIC INDUCTION OF EGR-1 PROMOTER ACTIVITY IN GENE THERAPY [Right-click to bookmark this link]
Former [2004/09]CHEMOTHERAPEUTIC INDUCTION OF EGR-1 PROMOTER ACTIVITY
[2011/26]
StatusNo opposition filed within time limit
Status updated on  23.11.2012
Database last updated on 18.09.2024
Most recent event   Tooltip30.05.2014Lapse of the patent in a contracting state
New state(s): LU		published on 02.07.2014  [2014/27]
Applicant(s)For all designated states
The University of Chicago
5640 South Ellis Avenue, Suite 405
Chicago, IL 60637 / US
For all designated states
DANA-FARBER CANCER INSTITUTE
44 Binney Street
Boston, MA 02115 / US
[2012/03]
Former [2005/46]For all designated states
The University of Chicago
5640 South Ellis Avenue, Suite 405
Chicago, IL 60637 / US
For all designated states
DANA-FARBER CANCER INSTITUTE
44 Binney Street
Boston, MA 02115 / US
Former [2004/09]For all designated states
The University of Chicago
5640 South Ellis Avenue, Suite 405
Chicago, IL 60637 / US
Inventor(s)01 / WEICHSELBAUM, Ralph, R.
1909 North Burling
Chicago, IL 60614 / US
02 / KUFE, Donald, W.
179 Grove Street
Wellesley, MA 02181 / US
03 / GUPTA, Vinay
1637 West Altgeld
Chicago, IL 60637 / US
04 / MAUCERI, Helen
2046 Burnham Place
Wheaton. IL 60187 / US
05 / PARK, James
526 E. 32nd ST. Unit E
Chicago, IL 60616 / US
06 / POSNER, Mitchell
442 W. Wellington 6W
Chicago, IL 60657 / US
 [2004/09]
Representative(s)Kremer, Simon Mark, et al
Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[N/P]
Former [2008/24]Kremer, Simon Mark, et al
Mewburn Ellis LLP York House, 23 Kingsway
London WC2B 6HP / GB
Former [2004/09]Fisher, Adrian John, et al
CARPMAELS & RANSFORD 43 Bloomsbury Square
London WC1A 2RA / GB
Application number, filing date02731264.405.04.2002
[2004/09]
WO2002US10733
Priority number, dateUS20010282040P06.04.2001         Original published format: US 282040 P
[2004/09]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO02080849
Date:17.10.2002
Language:EN
[2002/42]
Type: A2 Application without search report 
No.:EP1390075
Date:25.02.2004
Language:EN
The application published by WIPO in one of the EPO official languages on 17.10.2002 takes the place of the publication of the European patent application.
[2004/09]
Type: B1 Patent specification 
No.:EP1390075
Date:18.01.2012
Language:EN
[2012/03]
Search report(s)International search report - published on:US13.02.2003
(Supplementary) European search report - dispatched on:EP24.08.2007
ClassificationIPC:C12N15/67, C12N15/861, A61K48/00, C12N15/00, C12N15/09, C12N15/63, C12N15/85, C07H21/00, A61P35/04
[2007/38]
CPC:
A61K48/0066 (EP,US); A61K38/191 (EP,US); A61K45/06 (EP,US);
A61K48/0058 (EP,US); A61K48/0083 (EP,US); A61P35/04 (EP);
A61P43/00 (EP); C07K14/4702 (EP,US); C12N15/67 (EP,US);
C12N15/85 (EP,US); C12N15/86 (EP,US); C12N7/00 (EP,US);
A61K48/00 (EP,US); C12N2710/10343 (EP,US); C12N2830/002 (EP,US);
C12N2830/008 (EP,US); C12N2830/85 (EP,US); Y02A50/30 (US) (-)
Former IPC [2004/09]A61K48/00, C12N15/00, C12N15/09, C12N15/63, C12N15/85, C07H21/00
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   TR [2004/09]
TitleGerman:CHEMOTHERAPEUTISCHE EINLEITUNG DER EGR-1-PROMOTER-AKTIVITÄT IN GENTHERAPIE[2011/26]
English:CHEMOTHERAPEUTIC INDUCTION OF EGR-1 PROMOTER ACTIVITY IN GENE THERAPY[2011/26]
French:INDUCTION CHIMIOTHERAPEUTIQUE DE L'ACTIVITE DU PROMOTEUR EGR-1 DANS LA THERAPIE GENIQUE[2011/26]
Former [2004/09]CHEMOTHERAPEUTISCHE EINLEITUNG DER EGR-1-PROMOTER-AKTIVITÄT
Former [2004/09]CHEMOTHERAPEUTIC INDUCTION OF EGR-1 PROMOTER ACTIVITY
Former [2004/09]INDUCTION CHIMIOTHERAPEUTIQUE DE L'ACTIVITE DU PROMOTEUR EGR-1
Entry into regional phase05.11.2003National basic fee paid 
05.11.2003Search fee paid 
05.11.2003Designation fee(s) paid 
05.11.2003Examination fee paid 
Examination procedure03.10.2002Request for preliminary examination filed
International Preliminary Examining Authority: US
05.11.2003Examination requested  [2004/09]
07.01.2004Amendment by applicant (claims and/or description)
18.01.2008Despatch of a communication from the examining division (Time limit: M07)
29.07.2008Reply to a communication from the examining division
25.05.2011Date of oral proceedings
19.07.2011Minutes of oral proceedings despatched
29.07.2011Communication of intention to grant the patent
05.12.2011Fee for grant paid
05.12.2011Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  18.01.2008
Opposition(s)19.10.2012No opposition filed within time limit [2012/52]
Fees paidRenewal fee
07.11.2003Renewal fee patent year 03
20.04.2005Renewal fee patent year 04
26.04.2006Renewal fee patent year 05
27.04.2007Renewal fee patent year 06
25.04.2008Renewal fee patent year 07
29.04.2009Renewal fee patent year 08
26.04.2010Renewal fee patent year 09
06.04.2011Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT18.01.2012
BE18.01.2012
CY18.01.2012
DK18.01.2012
FI18.01.2012
NL18.01.2012
SE18.01.2012
TR18.01.2012
IE05.04.2012
LU05.04.2012
GR19.04.2012
CH30.04.2012
LI30.04.2012
MC30.04.2012
PT18.05.2012
[2014/27]
Former [2014/21]AT18.01.2012
BE18.01.2012
CY18.01.2012
DK18.01.2012
FI18.01.2012
NL18.01.2012
SE18.01.2012
TR18.01.2012
IE05.04.2012
GR19.04.2012
CH30.04.2012
LI30.04.2012
MC30.04.2012
PT18.05.2012
Former [2013/08]AT18.01.2012
BE18.01.2012
CY18.01.2012
DK18.01.2012
FI18.01.2012
NL18.01.2012
SE18.01.2012
IE05.04.2012
GR19.04.2012
CH30.04.2012
LI30.04.2012
MC30.04.2012
PT18.05.2012
Former [2013/07]AT18.01.2012
BE18.01.2012
CY18.01.2012
DK18.01.2012
FI18.01.2012
NL18.01.2012
SE18.01.2012
GR19.04.2012
CH30.04.2012
LI30.04.2012
MC30.04.2012
PT18.05.2012
Former [2012/50]BE18.01.2012
CY18.01.2012
DK18.01.2012
FI18.01.2012
NL18.01.2012
SE18.01.2012
GR19.04.2012
MC30.04.2012
PT18.05.2012
Former [2012/49]BE18.01.2012
CY18.01.2012
DK18.01.2012
FI18.01.2012
NL18.01.2012
SE18.01.2012
GR19.04.2012
PT18.05.2012
Former [2012/48]BE18.01.2012
CY18.01.2012
FI18.01.2012
NL18.01.2012
SE18.01.2012
GR19.04.2012
PT18.05.2012
Former [2012/41]BE18.01.2012
CY18.01.2012
FI18.01.2012
NL18.01.2012
GR19.04.2012
PT18.05.2012
Former [2012/37]BE18.01.2012
FI18.01.2012
NL18.01.2012
GR19.04.2012
PT18.05.2012
Former [2012/36]BE18.01.2012
NL18.01.2012
GR19.04.2012
Former [2012/35]BE18.01.2012
NL18.01.2012
Former [2012/33]BE18.01.2012
Documents cited:Search[T]  - PARK JAMES O ET AL, "Transcriptional control of viral gene therapy by cisplatin", JOURNAL OF CLINICAL INVESTIGATION, (200208), vol. 110, no. 3, ISSN 0021-9738, pages 403 - 410, XP002446418 [T] 1-40 * the whole document *

DOI:   http://dx.doi.org/10.1172/JCI200215548
 [Y]  - DATTA RAKESH ET AL, "Reactive oxygen intermediates target CC(A/T)-6GG sequences to mediate activation of the early growth response 1 transcription factor gene by ionizing radiation", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1993), vol. 90, no. 6, ISSN 0027-8424, pages 2419 - 2422, XP002446419 [Y] 1-40 * the whole document *

DOI:   http://dx.doi.org/10.1073/pnas.90.6.2419
 [Y]  - OHBA MOTOI ET AL, "Production of hydrogen peroxide by transforming growth factor-beta-1 and its involvement in induction of egr-1 in mouse osteoblastic cells", JOURNAL OF CELL BIOLOGY, (1994), vol. 126, no. 4, ISSN 0021-9525, pages 1079 - 1088, XP002446420 [Y] 1-40 * the whole document *

DOI:   http://dx.doi.org/10.1083/jcb.126.4.1079
 [XY]  - JOKI TATSUHIRO ET AL, "Modification of Doxorubicin molecule enhanced the early growth response gene 1 promoter activity", JIKEIKAI MEDICAL JOURNAL, (1996), vol. 43, no. 1, ISSN 0021-6968, pages 1 - 7, XP009088101 [X] 40 * the whole document * [Y] 1-39
 [XY]  - ARAI MASASHI ET AL, "Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca2+-ATPase gene transcription", CIRCULATION RESEARCH, (20000107), vol. 86, no. 1, ISSN 0009-7330, pages 8 - 14, XP002446421 [X] 40 * the whole document * [Y] 1-39
 [Y]  - DOROSHOW J H, "PREVENTION OF DOXORUBICIN-INDUCED KILLING OF MCF-7 HUMAN BREAST CANCER CELLS BY OXYGEN RADICAL SCAVENGERS AND IRON CHELATING AGENTS", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1986), vol. 135, no. 1, ISSN 0006-291X, pages 330 - 335, XP009088114 [Y] 1-40 * the whole document *

DOI:   http://dx.doi.org/10.1016/0006-291X(86)90981-2
 [Y]  - SODHI A ET AL, "INCREASED RELEASE OF HYDROGEN PEROXIDE AND SUPEROXIDE ANION BY MURINE MACROPHAGES IN-VITRO AFTER CISPLATIN TREATMENT", INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, (1986), vol. 8, no. 7, ISSN 0192-0561, pages 709 - 714, XP002446422 [Y] 1-40 * the whole document *

DOI:   http://dx.doi.org/10.1016/0192-0561(86)90006-8
 [Y]  - SULKOWSKA MARIOLA ET AL, "Cyclophosphamide-induced generation of reactive oxygen species. Comparison with morphological changes in type II alveolar epithelial cells and lung capillaries", EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY, (199806), vol. 50, no. 3, ISSN 0940-2993, pages 209 - 220, XP009088115 [Y] 1-40 * the whole document *
 [Y]  - UETA EISAKU ET AL, "Manganese superoxide dismutase negatively regulates the induction of apoptosis by 5-fluorouracil, peplomycin and gamma-Rays in squamous cell carcinoma cells", JAPANESE JOURNAL OF CANCER RESEARCH, (199905), vol. 90, no. 5, ISSN 0910-5050, pages 555 - 564, XP009088120 [Y] 1-40 * the whole document *
 [Y]  - VAN DER DONK WILFRED A ET AL, "Detection of a new substrate-derived radical during inactivation of ribonucleotide reductase from Escherichia coli by gemcitabine 5'-diphosphate", BIOCHEMISTRY, (19980505), vol. 37, no. 18, ISSN 0006-2960, pages 6419 - 6426, XP002446423 [Y] 1-40 * the whole document *

DOI:   http://dx.doi.org/10.1021/bi9729357
 [A]  - BONAVIDA B ET AL, "SYNERGY IS DOCUMENTED IN-VITRO WITH LOW-DOSE RECOMBINANT TUMOR NECROSIS FACTOR CISPLATIN AND DOXORUBICIN IN OVARIAN CANCER CELLS", GYNECOLOGIC ONCOLOGY, (1990), vol. 38, no. 3, ISSN 0090-8258, pages 333 - 339, XP002446424 [A] 1-40 * the whole document *

DOI:   http://dx.doi.org/10.1016/0090-8258(90)90068-V
International search[X]  - SEUNG ET AL., "Genetic radiotherapy overcomes tumor resistance to cytotoxic agents", CANCER RESEARCH, (19951201), vol. 55, pages 5561 - 5565, XP002955986
 [X]  - WEICHSELBAUM ET AL., "Gene therapy targeted by radiation preferentially radiosensitizes tumor cells", CANCER RESEARCH, (19940815), vol. 54, pages 4266 - 4269, XP002932030
 [X]  - STABA ET AL., "Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft", GENE THERAPY, (199803), vol. 5, pages 293 - 300, XP002955980

DOI:   http://dx.doi.org/10.1038/sj.gt.3300594
 [X]  - MAUCERI ET AL., "Tumor necrosis factor alpha (TNF-alpha) gene therapy targeted by ionizing radiation selectively damages tumor vasculature", CANCER RESEARCH, (19961001), vol. 54, pages 4311 - 4314, XP002936211
 [A]  - CARUSO M., "Gene therapy against cancer and HIV infection using the gene encoding herpes simplex virus thymidine kinase", MOLECULAR MEDICINE TODAY, (199605), vol. 1, pages 212 - 217, XP000670302

DOI:   http://dx.doi.org/10.1016/1357-4310(96)88774-0
 [A]  - HARBOUR ET AL., "Rb function in cell-cycle regulation and apoptosis", NATURE CELL BIOLOGY, (200004), vol. 2, pages E65 - E67, XP002955774

DOI:   http://dx.doi.org/10.1038/35008695
 [A]  - KREITMAN ET AL., "Targeting pseudomonas exotoxin to hematologic malignancies", CANCER BIOLOGY, (1995), vol. 6, pages 297 - 306, XP002955775

DOI:   http://dx.doi.org/10.1006/scbi.1995.0038
 [A]  - PEREZ R.P., "Cellular and molecular determinants of cisplatin resistance", EUROPEAN JOURNAL OF CANCER, (1998), vol. 34, no. 10, pages 1535 - 1542, XP004285043

DOI:   http://dx.doi.org/10.1016/S0959-8049(98)00227-5
 [A]  - SARTORIUS ET AL., "Molecular mechanisms of death-receptor-mediated apoptosis", CHEMBIOCHEM., (2001), vol. 2, pages 20 - 29, XP002955776

DOI:   http://dx.doi.org/10.1002/1439-7633(20010105)2:1<20::AID-CBIC20>3.0.CO;2-X
 [A]  - GONZALEZ ET AL., "Is cisplatin-induced cell death always produced by apoptosis?", MOLECULAR PHARMOCOLOGY, (2001), vol. 59, pages 657 - 663, XP002955777
Examination   - MYERS C, "The role of iron in doxorubicin-induced cardiomyopathy.", SEMINARS IN ONCOLOGY AUG 1998 LNKD- PUBMED:9768818, (199808), vol. 25, no. 4 Suppl 10, ISSN 0093-7754, pages 10 - 14
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.